Purealidins J—R, New Bromotyrosine Alkaloids from the Okinawan Marine Sponge *Psammaplysilla purea*

Jun'ichi KOBAYASHI,*[,a] Kaori HONMA,[a] Takuma SASAKI,[b] and Masashi TSUDA[a]

Faculty of Pharmaceutical Sciences, Hokkaido University,[a] Kita-ku, Sapporo 060, Japan and Cancer Research Institute, Kanazawa University,[b] Takara-machi, Kanazawa 920, Japan.
Received October 11, 1994; accepted November 21, 1994

Nine new bromotyrosine alkaloids, purealidins J—R (1—9), have been isolated from the Okinawan marine sponge *Psammaplysilla purea* and the structures were elucidated on the basis of spectroscopic data. A hydroxy group at C-1 of purealidins M—O (4—6) may be biosynthetically derived from ring-opening of a spirocyclohexadienylisoxazole unit of purealidin J (1), aerophobin-1 (10), and purealidin L (3), respectively. Purealidins N (5), P (7), and Q (8) were cytotoxic to tumor cell lines, while purealidins J (1), K (2), P (7), and Q (8) showed moderate inhibitory activity against epidermal growth factor (EGF) receptor kinase.

Key words sponge; *Psammaplysilla purea*; bromotyrosine alkaloid; purealidin; cytotoxic; epidermal growth factor receptor kinase

Marine sponges of the order Verongidae have been found to contain a number of bromotyrosine alkaloids[1)] such as aeroplysinin 1,[2)] fistularin 3,[3)] and bastadin 1.[4)] In our search for bioactive substances from marine organisms,[5)] a series of bromotyrosine alkaloids have been isolated from a Verongid marine sponge *Psammaplysilla purea*.[6)] Further examination of the extract of *P. purea* resulted in isolation of nine new bromotyrosine-derived alkaloids, purealidins J—R (**1**—**9**), which might be closely related to one another on biogenesis of them. This paper describes the isolation and structure elucidation of **1**—**9**.

EtOAc-soluble material of the methanolic extract of the sponge *P. purea* collected off Ishigaki island, Okinawa, was separated on silica gel and C_{18} columns, and C_{18} HPLC to yield purealidins J (**1**, 0.004% wet weight), K (**2**, 0.002%), L (**3**, 0.0002%), M (**4**, 0.002%), N (**5**, 0.0003%), O (**6**, 0.0001%), P (**7**, 0.0008%), Q (**8**, 0.0004%), and R (**9**, 0.0004%), which were obtained as the trifluoroacetic acid (TFA) salts, except for **5** and **9**, together with known related compounds, aerophobin-1[7)] (**10**, 0.005%), purealin[6a)] (**11**), and purealidin B.[6d)]

Purealidins J—L (**1**—**3**) revealed pseudomolecular ions in the ratio of 1:2:1 at m/z 490, 492, and 494 (**1**), at m/z 506, 508, and 510 (**2**), and at m/z 494, 496, and 498 (**3**), respectively, in the FAB-MS spectra, indicating the presence of two bromine atoms in each molecule. HR-FAB-MS data of **1**—**3** revealed the molecular formulae, $C_{15}H_{17}Br_2N_5O_4$ (m/z 491.9682, $M^+ + 2 + H$, $\Delta -2.3$ mmu), $C_{15}H_{17}Br_2N_5O_5$ (m/z 507.9672, $M^+ + 2 + H$, $\Delta + 1.8$ mmu), and $C_{15}H_{21}Br_2N_5O_4$ (m/z 496.0035, $M^+ + 2 + H$, $\Delta + 1.7$ mmu), respectively. IR absorptions at 3400 and 1680—1660 cm^{-1} in **1**—**3** were attributed to NH/OH and amide carbonyl groups, respectively. Comparison of the ^1H- and ^{13}C-NMR data (Table I) of **1**—**3** with those of aerophobin-1 (**10**) indicated that **1**—**3** possessed a common spirocyclohexadienylisoxazole unit with different structures for each C-10—C-14 segment.

Observation that purealidin J (**1**, $[\alpha]_D^{21}$ $+24°$ ($c=0.98$, MeOH)) was positive to Sakaguchi test suggested the presence of guanidine group(s). The ^1H-NMR spectrum of **1** containing an NH_2 (δ_H 7.40, 2H) and an olefin proton (δ_H 6.62) signals was similar to that of the 2-aminohistamine unit in purealin (**11**) or purealidin A.[6c)] The carbon chemical shifts (Table I) of C-12, C-13, and C-14 of **1** were coincident with those (δ_C 124.11, 109.00, and 146.74, respectively) of the corresponding 2-

TABLE I. ^{13}C-NMR Data for Purealidins J—O and R (**1**—**6** and **9**) and Aerophobin-1 (**10**)

Positn.	**1**[a)]	**2**[a)]	**3**[b)]	**4**[c)]	**5**[b)]	**6**[b)]	**9**[b)]	**10**[a)]
1	73.6	73.6	76.3	152.8	155.0	155.2	75.5	73.5
2	113.0	113.1	114.9	107.6	108.8	108.2	114.2	113.1
3	147.1	147.2	150.1	152.7	154.3	153.6	149.3	147.1
4	120.8	120.9	123.5	105.5	107.4	108.2	122.7	120.9
5	131.2	131.3	133.0	132.2	134.6	135.4	132.3	131.2
6	90.2	90.4	93.2	122.0	122.7	123.7	92.6	90.3
7	39.2[d)]	39.5[d)]	40.1[d)]	27.0	25.5	26.4	40.0	39.4
8	154.3	154.3	159.5	150.3	151.5	152.6	155.2	154.4
9	158.9	157.9	162.5	164.7	167.3	167.8	163.6	159.1
10	37.3	35.0	40.5	37.6	39.2	40.7		37.7
11	24.2	30.2	28.3	24.7	25.8	29.0		24.1
12	124.1	56.9	28.0	124.2	132.2	28.4		130.8
13	109.4	174.8	42.9	109.3	117.7	42.9		161.1
14	146.9	159.2	156.1	146.7	134.9	156.4		133.6
3-OCH_3	59.6	59.7	61.2	60.0	60.8	61.7	60.4	59.6

a) In DMSO-d_6. *b*) In MeOH-d_4. *c*) In DMSO-d_6 with a drop of 1 N HCl. *d*) This carbon signal overlapped the DMSO signal.

* To whom correspondence should be addressed.

© 1995 Pharmaceutical Society of Japan

NII-Electronic Library Service



Fig. 1



Fig. 2

aminoimidazole ring in **11**. Thus the structure of purealidin J was elucidated to be **1**.

The molecular weight of purealidin K (**2**, $[\alpha]_D^{24}$ +26° (c=0.38, MeOH)) was larger than that of **1** by 16 Da. The signals due to NH (δ_H 9.64) and a carbonyl carbon (δ_C 174.8) observed in the ^{1}H- and ^{13}C-NMR spectra, respectively, were indicative of the presence of an additional amide carbonyl group. The position of the amide carbonyl (C-13) was assigned by HMBC correlations for H-11/C-12, H-11/C-13 and 13-NH/C-13. The chemical shifts at C-12, C-13, and C-14 in **2** were close to those (δ_C 61.7, 174.1, and 160.5, respectively) of the aminoimidazolone ring in oxysceptrin[8] (**12**). Thus the structure of purealidin K was assigned to be **2**. Purealidin K (**2**) was subjected to ozonolysis followed by oxidation with H_2O_2 and subsequently acid hydrolysis. Standard amino acid analysis and chiral HPLC analyses of the hydrolysate revealed D- and L-2,4-diaminobutyric acid in the ratio of 1 : 1, so

NII-Electronic Library Service

that C-12 in **2** was racemic.

The ^{13}C-NMR data (Table I) of purealidin L (**3**, $[\alpha]_D^{24}$ $+27°$ ($c=0.18$, MeOH)) showed characteristic resonances due to four sp^3 methylenes at δ_C 42.9, 40.5, 28.3, and 28.0 and an sp^2 quaternary carbon at δ_C 156.1. The sp^2 carbon chemical shift at C-14 as well as positive coloration in the Sakaguchi test implied the presence of a guanidino group. An agmatine (4-(aminobutyl)guanidine) moiety in **3** was assigned by the following ^{1}H–^{1}H COSY cross-peaks: 9-NH/H_2-10, H_2-10/H_2-11, H_2-11/H_2-12, H_2-12/H_2-13, and H_2-13/13-NH. Thus the structure of purealidin L was elucidated to be **3**.

The molecular formula, $C_{15}H_{16}Br_2N_4O_4$, of purealidin M (**4**) was established by the HR-FAB-MS (*m/z* 476.9564, $M^+ + 2 + H$, $\Delta -3.2$ mmu). Though the ^{1}H- and ^{13}C-NMR data (Table I) of **4** were similar to those of ianthelline[9] (**13**), differences were found for the aromatic ring (C-1—C-6): **13** possessed a symmetrical tetrasubstituted benzene ring, while the ^{1}H-NMR spectrum of **4** showed signals due to a pentasubstituted benzene ring (δ_H 7.26, 1H) and an additional phenol hydroxy group (δ_H 10.48). Assignment of C-1—C-6 was based on HMBC correlations for H-5/C-1, H-5/C-3, H-5/C-4, H-5/C-6, H_2-7/C-1, H_2-7/C-5, H_2-7/C-6, and 3-OMe/C-3. Thus the structure of purealidin M was determined to be **4**. *E*-Geometry of the oxime at C-8 of **4**—**6** was inferred from the carbon chemical shift of C-7 (δ_C 25.5—27.0).[10]

The molecular formulae, $C_{15}H_{17}Br_2N_5O_4$ and $C_{15}H_{21}Br_2N_5O_4$, of purealidins N (**5**) and O (**6**) were the same as those of aerophobin-1 (**10**) and purealidin L (**3**), respectively. Comparison of the ^{1}H- and ^{13}C-NMR data (Table I) of **5** and **6** with those of purealidin M (**4**) suggested that **5** and **6** had the same pentasubstituted bromotyrosine moiety (C-1—C-9) as **4**. The carbon resonances of C-10—C-14 in **5** were similar to those of the histamine unit in **10**, while those for **6** corresponded to the agmatine unit in **3**. The structures of purealidins N and O were, therefore, concluded to be **5** and **6**, respectively.

Purealidin P (**7**) showed the pseudomolecular ions at *m/z* 742, 744, 746, 748, and 750 (1:4:6:4:1) in the FAB-MS spectrum, and the molecular formula, $C_{23}H_{27}Br_4N_3O_5$, was established by the HR-FAB-MS (*m/z* 745.8776, $M^+ + 4 + H$, $\Delta +5.5$ mmu). The ^{1}H- and ^{13}C-NMR data for **7** were almost same as those of purealidin B[6d] except for an *N*-methyl resonance (δ_C 59.2), which was shifted to higher field than that (δ_C 64.2) of purealidin B. A 6H singlet proton signal resonated at δ_H 2.78 was assigned to be a dimethylamino group. NOEs for H_2-15/H_2-17 and H_2-18/18-NMe_2 in addition to the above data established the structure of purealidin P to be **7**.

Purealidin Q (**8**) possessed the same molecular formula as that of **7**, and the ^{1}H- and ^{13}C-NMR data suggested that **7** and **8** had a common partial structure. Analyses of the ^{1}H–^{1}H COSY spectrum of **8** revealed proton connectivities of 9-NH—H_2-11 and H_2-16—H_2-18, and the NOE observed for H_2-18/18-NMe_2 suggested that an *N*-dimethyl group was attached to a C_3 unit. Thus the structure of purealidin Q was assigned to be **8**.

Purealidin R (**9**, $[\alpha]_D^{24}$ $+86°$ ($c=0.19$, MeOH)) showed molecular ions at *m/z* 380, 382, and 384 (1:2:1) in the EI-MS spectrum. The molecular formula, $C_{10}H_{10}Br_2N_2O_4$, was determined by HR-EI-MS (*m/z* 381.8901, $M^+ + 2$, $\Delta +0.3$ mmu). The ^{1}H- and ^{13}C-NMR data (Table I) revealed the presence of a spirocyclohexadienylisoxazole unit and a primary amide NH_2, thus suggesting that the structure of purealidin R is **9**.

Stereochemistry at C-1 and C-6 of the spiroisoxazole ring in purealidins J (**1**), K (**2**), L (**3**), P (**7**), Q (**8**), and R (**9**), and aerophobin-1 (**10**) was deduced to be *trans* from the proton chemical shift (*ca.* δ_H 4.05) of H-1 in CD_3OD.[11] These compounds were found to be dextrorotatory from the signs of optical rotations and Cotton effects at 248 and 284 nm in the CD spectra, indicating that absolute configurations at C-1 and C-6 are 1*R* and 6*S*.[6a,6d,12] The $[\alpha]_D$ value (+68°) of compound **10** is smaller than that ($[\alpha]_D$ +139°) in the literature,[7] indicating that aerophobin-1 (**10**) isolated from this sponge may be an enantiomeric mixture containing an excess of the dextrorotamer (*ca.* 50% ee).

Purealidins M (**4**), N (**5**) and O (**6**) are the second examples[13] of bromotyrosines with a phenolic hydroxy group at C-1 from natural origin.[14] Biosynthetically compounds **1**—**9** may be closely related to one another, presumably being generated through condensation of bromotyrosine units (C-1—C-9) with various amines such as agmatine, brominated tyramine with C_3 units, ammonia, or histamine. The spirocyclohexadienylisoxazole ring may be derived from an arene oxide intermediate (**a**) as proposed by Andersen and Faulkner[15] (Chart 1). Ring-opening of the spirocyclohexadienylisoxazole units of purealidins J (**1**), L (**3**), and aerophobin-1 (**10**) may generate purealidins M (**4**), O (**6**), and N (**5**), respectively, with a hydroxy group at C-1. The aminohistamine units of **1** and **4** may be biogenetically derived from the agmatine units of **3** and **6**. Cyclization between C-12 and 14-N in **3** may afford **1**, which is probably oxygenated to yield **2**.

Purealidins N (**5**), P (**7**), and Q (**8**) exhibited cytotoxicity against murine lymphoma L1210 cells (IC_{50} values: 0.07, 2.8, and 0.95 μg/ml, respectively) and human epidermoid carcinoma KB cells (IC_{50}: 0.074, 7.6, and 1.2 μg/ml, respectively) *in vitro*, while purealidins J—M (**1**—**4**), O (**6**) and R (**9**), and aerophobin-1 (**10**) had no cytotoxicity (IC_{50}



Chart 1. Plausible Biogenetic Path of Bromotyrosines with a Spirocyclohexadienylisoxazole Unit and/or a Hydroxy Group at C-1

NII-Electronic Library Service

$>10\,\mu$g/ml). Purealidins J (**1**), K (**2**), P (**7**), and Q (**8**) showed inhibitory activity against epidermal growth factor (EGF) receptor kinase[16] (IC_{50}: 23, 14, 18, and 11 μg/ml, respectively).

Experimental

General Methods UV and IR spectra were taken on a JASCO Ubest-35 and a JASCO IR Report-100 spectrometer, respectively. ^{1}H- and ^{13}C-NMR spectra were conducted with a JEOL EX-400 and GSX-270 spectrometer in CD_3OD and DMSO-d_6. The resonances of MeOH at δ_H 3.30 and δ_C 49.0 were used as internal references for ^{1}H- and ^{13}C-NMR spectra, respectively. The resonances of residual DMSO at δ_H 2.50 and δ_C 39.5 were used as internal references for ^{1}H- and ^{13}C-NMR spectra, respectively. FAB-MS spectra were recorded employing a JEOL HX-110 spectrometer by using glycerol as a matrix. EI-MS spectra were obtained on a JEOL DX-303 spectrometer operating at 70 eV.

Collection, Extraction, and Isolation The dark brown sponge, *Psammaplysilla purea* Carter, was collected off Ishigaki Island, Okinawa and kept frozen until needed. The sponge (1.5 kg, wet weight) was extracted with MeOH (1.3 l and then 1 l). After evaporation under reduced pressure the residue (55.6 g) was partitioned between EtOAc (500 ml × 3) and H_2O (500 ml). The EtOAc soluble material (3.30 g) was subjected to a silica gel column with $CHCl_3$–*n*-BuOH–AcOH–H_2O (1.5 : 6 : 1 : 1). The fraction (134 mg, 760—940 ml) was chromatographed on a C_{18} column (Develosil LOP ODS 24S, Nomura Chemical, 30 × 300 mm) with CH_3CN–H_2O–CF_3CO_2H (35 : 65 : 0.1) and then MeOH to give two fractions. The fraction (34 mg, 45—100 ml) was separated by C_{18} HPLC (YMC Pack AM323 ODS, 10 × 250 mm; eluent, CH_3CN–H_2O–CF_3CO_2H, 35 : 75 : 0.1; flow rate, 2.5 ml/min; UV detection at 254 nm) to afford purealidins J (**1**, 0.004%, t_R 10.8 min), K (**2**, 0.002%, t_R 10.2 min) and L (**3**, 0.0002%, t_R 11.5 min). The other fraction (36.4 mg) eluted with MeOH from the C_{18} column was subjected to C_{18} HPLC (YMC Pack AM323 ODS, 10 × 250 mm; eluent, CH_3CN–H_2O–CF_3CO_2H, 42 : 58 : 0.1; flow rate, 2.5 ml/min; UV detection at 254 nm) to afford purealidins N (**5**, 0.0003%, t_R 12.0 min), O (**6**, 0.0001%, t_R 14.0 min), and R (**9**, 0.0004%, t_R 19.0 min). The other fraction (219.2 mg) eluted at 950—1080 ml from the first silica gel column was subjected to a C_{18} column (Develosil LOP ODS 24S, 30 × 300 mm; eluent, CH_3CN–H_2O–CF_3CO_2H, 45 : 55 : 0.1) followed by purification by C_{18} HPLC (YMC Pack AM323 ODS, 10 × 250 mm; eluent, CH_3CN–H_2O–CF_3CO_2H, 45 : 55 : 0.1; flow rate, 2.5 ml/min; UV detection at 254 nm) to afford purealidins M (**4**, 0.002%, t_R 8.4 min), P (**7**, 0.0008%, t_R 17.4 min), and Q (**8**, 0.0004%, t_R 16.2 min) together with aerophobin-1 (**10**, 0.005%).

Purealidin J (1) TFA Salt Colorless oil, $[\alpha]_D^{21}$ +24° (c=0.98, MeOH). IR (KBr): 3400, 2930, 2845, 1680, 1540, 1430, 1200, 1135 cm^{-1}. UV λ_{max}^{MeOH} nm (ε): 277 (1700), 284 (1400). CD (c=0.64 × 10^{-4}, MeOH) $\Delta\varepsilon^{30}$ (nm): +2.2 (255), +2.1 (287). ^{1}H-NMR (DMSO-d_6) δ: 2.61 (2H, t, J=6.4 Hz, H_2-11), 3.19 (1H, d, J=18.6 Hz, H-7), 3.37 (2H, br t, J=6.4 Hz, H_2-10), 3.61 (1H, d, J=18.6 Hz, H-7), 3.64 (3H, s, 3-OMe), 3.91 (1H, d, J=6.4 Hz, H-1), 6.37 (1H, d, J=6.4 Hz, 1-OH), 6.58 (1H, s, H-5), 6.62 (1H, br s, H-13), 7.40 (2H, s, 14-NH_2), 8.63 (1H, t, J=5.6 Hz, 9-NH), 11.71 (1H, br s, 12-NH), 12.13 (1H, br s, 13-NH). ^{13}C-NMR: see Table I. FAB-MS m/z: 490, 492, 494 (M$^+$+H, 1 : 2 : 1). HR-FAB-MS Calcd for $C_{15}H_{19}Br_2N_5O_4$ (M+2+H)$^+$: 491.9705. Found: 491.9682.

Purealidin K (2) TFA Salt Colorless oil, $[\alpha]_D^{24}$ +26° (c=0.38, MeOH). IR (KBr): 3400, 2920, 2850, 1670, 1540, 1430, 1200, 1135, 1125 cm^{-1}. UV λ_{max}^{MeOH} nm (ε): 231 (6300), 284 (2400). CD (c=0.73 × 10^{-4}, MeOH) $\Delta\varepsilon^{30}$ (nm): +2.3 (255), +2.1 (289). ^{1}H-NMR (DMSO-d_6) δ: 1.86 (1H, m, H-11), 1.96 (1H, m, H-11), 3.19 (1H, d, J=18.0 Hz, H-7), 3.35 (2H, m, H_2-10), 3.62 (1H, d, J=18.0 Hz, H-7), 3.65 (3H, s, 3-OMe), 3.92 (1H, d, J=6.3 Hz, H-1), 4.30 (1H, dd, J=4.9, 7.8 Hz, H-12), 6.36 (1H, d, J=6.3 Hz, 1-OH), 6.58 (1H, s, H-5), 8.63 (1H, t, J=5.1 Hz, 9-NH), 8.96 (2H, s, 14-NH_2), 9.64 (1H, br s, 13-NH), 12.5 (1H, br, 12-NH). ^{13}C-NMR: see Table I. FAB-MS m/z: 506, 508, 510 (M$^+$+H, 1 : 2 : 1). HR-FAB-MS Calcd for $C_{15}H_{18}Br_2N_5O_5$ (M+2+H)$^+$: 507.9654. Found: 507.9672.

Purealidin L (3) TFA Salt Colorless oil, $[\alpha]_D^{24}$ +27° (c=0.18, MeOH). IR (KBr): 3400, 2920, 1660, 1520, 1470, 1210 cm^{-1}. UV λ_{max}^{MeOH} nm (ε): 228 (8600), 290 (3400). CD (c=1.4 × 10^{-4}, MeOH) $\Delta\varepsilon^{30}$ (nm): +2.3 (248), +1.9 (284). ^{1}H-NMR (DMSO-d_6) δ: 1.45 (2H, m, H_2-12), 1.47 (2H, m, H_2-11), 3.09 (2H, m, H_2-13), 3.16 (2H, m, H_2-10), 3.19 (1H, d, J=18.2 Hz, H-7), 3.62 (1H, d, J=18.2 Hz, H-7), 3.64 (3H, s, 3-OMe), 3.91 (1H, d, J=7.9 Hz, H-1), 6.34 (1H, d, J=7.9 Hz, 1-OH), 6.57 (1H, s, H-5), 7.1—7.3 (4H, br, 14-C(–NH_2)NH_2), 7.44 (1H, br s, 13-NH), 8.54 (1H, t, J=5.8 Hz, 9-NH). ^{13}C-NMR see Table I. FAB-MS m/z: 494, 496, 498 (M$^+$+H, 1 : 2 : 1). HR-FAB-MS Calcd for $C_{15}H_{22}Br_2N_5O_4$, (M+2+H)$^+$: 496.0018. Found: 496.0035.

Purealidin M (4) TFA Salt Colorless oil. IR (KBr): 3400, 2920, 1680, 1520, 1470, 1200, 1135, 1120 cm^{-1}. UV λ_{max}^{MeOH} nm (ε): 277 (1700), 284 (1400). ^{1}H-NMR (DMSO-d_6) δ: 2.63 (2H, t, J=6.9 Hz, H_2-11), 3.40 (2H, dt, J=5.9, 6.9 Hz, H_2-10), 3.70 (2H, s, H_2-7), 3.74 (3H, s, 3-OMe), 6.60 (1H, s, H-13), 7.26 (1H, s, H-5), 7.33 (2H, s, 14-NH_2), 8.55 (1H, t, J=5.9 Hz, 9-NH), 10.48 (1H, br s, 1-OH), 11.55 (1H, br s, 12-NH), 11.99 (1H, br s, 13-NH), 12.19 (1H, s, 8-NOH). ^{13}C-NMR: see Table I. FAB-MS m/z: 490, 492, 494 (M$^+$+H, 1 : 2 : 1). HR-FAB-MS Calcd for $C_{15}H_{18}Br_2N_5O_4$ (M+2+H)$^+$: 491.9705. Found 491.9740.

Purealidin N (5) Colorless oil. IR (KBr): 3400, 2920, 2845, 1680, 1520, 1135, 1120 cm^{-1}. UV λ_{max}^{MeOH} nm (ε): 235 (2600), 290 (2800). ^{1}H-NMR (DMSO-d_6) δ: 2.85 (2H, t, J=6.7 Hz, H_2-11), 3.48 (2H, dt, J=5.9, 6.7 Hz, H_2-10), 3.70 (2H, s, H_2-7), 3.74 (3H, s, 3-OMe), 7.26 (1H, s, H-5), 7.40 (1H, s, H-13), 8.59 (1H, t, J=5.9 Hz, 9-NH), 8.89 (1H, s, H-14), 10.45 (1H, br s, 1-OH), 12.20 (1H, s, 8-NOH), 14.1 (1H, br s, 13-NH). ^{13}C-NMR: see Table I. FAB-MS m/z: 475, 477, 479 (M$^+$+H, 1 : 2 : 1). HR-FAB-MS Calcd for $C_{15}H_{17}Br_2N_4O_4$ (M+2+H)$^+$: 476.9596. Found: 476.9564.

Purealidin O (6) TFA Salt Colorless oil. IR (KBr): 3400, 2920, 2850, 1680, 1635, 1135 cm^{-1}. UV λ_{max}^{MeOH} nm (ε): 235 nm (2600), 287 (700). ^{1}H-NMR (DMSO-d_6) δ: 1.42 (2H, m, H_2-12), 1.44 (2H, m, H_2-11), 3.09 (2H, m, H_2-13), 3.18 (2H, m, H_2-10), 3.70 (2H, s, H_2-7), 3.74 (3H, s, 3-OMe), 7.1—7.3 (4H, br, 14-C (–NH_2)NH_2), 7.31 (1H, s, H-5), 7.43 (1H, br s, 13-NH), 8.56 (1H, t, J=5.9 Hz, 9-NH), 10.68 (1H, br s, 1-OH), 12.17 (1H, s, 8-NOH). ^{13}C-NMR: see Table I. FAB-MS m/z: 494, 496, 498 (M$^+$+H, 1 : 2 : 1). HR-FAB-MS Calcd for $C_{15}H_{22}Br_2N_5O_4$ (M+2+H)$^+$: 496.0018. Found: 496.0028.

Purealidin P (7) TFA Salt Colorless oil, $[\alpha]_D^{19}$ +6.6° (c=0.75, MeOH). IR (KBr): 3400, 2940, 2845, 1670, 1520, 1470, 1135, 1120 cm^{-1}. UV λ_{max}^{MeOH} nm (ε): 277 (1700), 284 (1400). CD (c=0.37 × 10^{-4}, MeOH) $\Delta\varepsilon^{30}$ (nm): +0.9 (248), +1.1 (284). ^{1}H-NMR (DMSO-d_6) δ_H: 2.01 (2H, m, H_2-11), 2.78 (6H, s, 18-NMe_2), 2.93 (2H, t, J=8.1 Hz, H_2-17), 3.23 (1H, d, J=18.0 Hz, H-7), 3.35 (2H, m, H_2-18), 3.41 (2H, m, H_2-10), 3.62 (1H, d, J=18.0 Hz, H-7), 3.65 (3H, s, 3-OMe), 3.92 (1H, d, J=8.1 Hz, H-1), 3.97 (2H, t, J=6.3 Hz, H_2-12), 6.36 (1H, d, J=8.1 Hz, 1-OH), 6.59 (1H, s, H-5), 7.64 (2H, s, H-15, 15′), 8.57 (1H, t, J=5.8 Hz, 9-NH). ^{13}C-NMR (CD_3OD) δ_C: 30.3 (t, C-17), 30.6 (t, C-11), 37.9 (t, C-10), 40.1 (t, C-7), 43.6 (2C, q, 18-NMe_2), 59.2 (t, C-18), 60.4 (q, 1-OMe), 72.3 (t, C-12), 75.5 (d, C-1), 92.5 (s, C-6), 114.2 (s, C-2), 119.5 (2C, s, C-14, 14′), 122.8 (s, C-4), 132.3 (d, C-5), 134.4 (d, C-15), 134.5 (d, C-15′), 136.5 (s, C-16), 149.4 (s, C-3), 153.7 (s, C-13), 155.3 (s, C-8), 161.6 (s, C-9). FAB-MS m/z: 742, 744, 746, 748, 750 (M$^+$+H, 1 : 4 : 6 : 4 : 1). HR-FAB-MS Calcd for $C_{23}H_{28}Br_4N_3O_5$ (M+4+H)$^+$: 745.8721. Found: 745.8776.

Purealidin Q (8) TFA Salt Colorless oil, $[\alpha]_D^{19}$ +9.1° (c=0.39, MeOH). IR (KBr): 3400, 2940, 2850, 1675, 1470, 1200, 1135, 1120 cm^{-1}. UV λ_{max}^{MeOH} nm (ε): 277 (1700), 284 (1400). CD (c=0.52 × 10^{-4}, MeOH) $\Delta\varepsilon^{30}$ (nm): +1.5 (250), +1.4 (284). ^{1}H-NMR (DMSO-d_6) δ_H: 2.15 (2H, m, H_2-17), 2.76 (2H, t, J=6.9 Hz, H_2-11), 2.83 (6H, s, 18-NMe_2), 3.18 (1H, d, J=18.2 Hz, H-7), 3.36 (2H, m, H_2-10), 3.40 (2H, m, H_2-18), 3.60 (1H, d, J=18.2 Hz, H-7), 3.64 (3H, s, 3-OMe), 3.92 (1H, d, J=8.2 Hz, H-1), 3.99 (2H, t, J=6.3 Hz, H_2-16), 6.34 (1H, d, J=8.2 Hz, 1-OH), 6.57 (1H, s, H-5), 7.54 (2H, s, H-15, 15′), 8.58 (1H, t, J=5.7 Hz, 9-NH). ^{13}C-NMR (CD_3OD) δ_C: 26.4 (t, C-17), 35.1 (t, C-11), 40.1 (t, C-10), 41.4 (t, C-7), 43.7 (2C, q, 18-NMe_2), 57.2 (t, C-18), 60.4 (q, 1-OMe), 71.2 (t, C-16), 75.5 (d, C-1), 92.4 (s, C-6), 114.2 (s, C-2), 118.8 (2C, s, C-14, 14′), 122.8 (s, C-4), 132.2 (d, C-5), 134.5 (d, C-13), 134.6 (d, C-13′), 140.3 (s, C-12), 149.3 (s, C-3), 152.2 (s, C-15), 155.2 (s, C-8), 161.6 (s, C-9). FAB-MS m/z: 742, 744, 746, 748, 750 (M$^+$+H, 1 : 4 : 6 : 4 : 1). HR-FAB-MS Calcd for $C_{23}H_{28}Br_4N_3O_5$ (M+4+H)$^+$: 745.8721. Found: 745.8729.

Purealidin R (9) Colorless oil, $[\alpha]_D^{24}$ +86° (c=0.19, MeOH). IR (KBr): 3400, 2940, 1675, 1135, 1120 cm^{-1}. UV λ_{max}^{MeOH} nm (ε): 228 (8000), 290 (2000). CD (c=0.52 × 10^{-4}, MeOH) $\Delta\varepsilon^{30}$ (nm): +4.0 (248), +4.3 (284). ^{1}H-NMR (DMSO-d_6) δ: 3.18 (1H, d, J=18.2 Hz, H-7), 3.60 (1H, d, J=18.2 Hz, H-7), 3.65 (3H, s, 3-OMe), 3.92 (1H, d, J=6.2 Hz, H-1), 6.35 (1H, d, J=6.2 Hz, 1-OH), 6.58 (1H, s, H-5), 7.58 (1H, br s, NH-9), 7.82 (1H, br s, NH-9). ^{13}C-NMR: see Table I. EI-MS m/z: 380, 382, 384

NII-Electronic Library Service

($M^+ + H$, 1:2:1). HR-EI-MS Calcd for $C_{10}H_{10}Br_2N_2O_4$ $(M+2)^+$: 381.8898. Found: 381.8901.

Determination of the Stereochemistry of C-12 in Purealidin K (2) A solution of purealidin K (**2**, 1.0 mg) in MeOH (100 μl) was bubbled with O_3 at $-78\,°C$ for 1 min. After removal of excess O_3 with a stream of N_2, the solvent was evaporated under reduced pressure, and to the residue were added HCO_2H (250 ml) and 35% H_2O_2 (25 μl). The mixture was stirred for 1 h at 0 °C and then for 18 h at room temperature. The solvent was evaporated, and then the residue was dissolved in 6 N HCl (100 μl); this solution was heated at 110 °C for 24 h. Standard amino acid analysis was performed on a Hitachi amino acid autoanalyzer (Model 835, column #2617 4.0 × 250 mm) with Na buffer at a flow rate of 0.275 ml/min and detected at 570 nm. 2,4-Diaminobutyric acid (t_R 96.42 min) was found in the hydrolysate. The absolute stereochemistry of 2,4-diaminobutyric acid was examined by chiral HPLC analysis (Sumichiral OA-6000, Sumika Chemical Analysis Service, Ltd., 4.6 × 150 mm; flow rate, 0.5 ml/min; UV detection at 254 nm; eluent, 1 mM aqueous $CuSO_4$). The retention times of authentic L- and D-2,4-diaminobutyric acid were 30.5 and 29.6 min, respectively. The retention times of the 2,4-diaminobutyric acid in the hydrolysate was found to be 30.5 and 29.6 min (ratio of *ca.* 1:1).

Acknowledgments We thank Mr. Z. Nagahama for his help with collection of the sponge. We are also grateful to Banyu Pharmaceutical Co., Ltd., for EGF receptor kinase assay. This work was partly supported by a Grant-in-Aid from Ciba-Geigy Foundation (Japan) for the Promotion of Science and by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, and Culture of Japan.

References

1) J. Kobayashi, M. Ishibashi, "The Alkaloids," Vol. 41, ed. by A Brossi, G. A. Cordell, Academic Press, San Diego, 1992, pp. 41—124.
2) *a*) E. Fattorusso, L. Minale, G. Sodano, *J. Chem. Soc., Chem. Commun.*, **1970**, 751; *b*) E. Fattorusso, L. Minale, G. Sodano, *J. Chem. Soc., Perkin Trans 1*, **1972**, 16.
3) Y. Gopichand, F. J. Schmitz, *Tetrahedron Lett.*, **1979**, 3921.
4) R. Kazlauskas, R. O. Lidgard, P. T. Murphy, R. J. Wells, *Tetrahedron Lett.*, **21**, 2277 (1980).
5) *a*) M. Tsuda, T. Sasaki, J. Kobayashi, *J. Org. Chem.*, **59**, 3734 (1994); *b*) J. Kobayashi, M. Tsuda, N. Kawasaki, K. Matsumoto, T. Adachi, *Tetrahedron Lett.*, **35**, 4384 (1994); *c*) M. Tsuda, N. Kawasaki, J. Kobayashi, *ibid.*, **35**, 4387 (1994).
6) *a*) H. Nakamura, H. Wu, J. Kobayashi, Y. Ohizumi, Y. Hirata, *Tetrahedron Lett.*, **26**, 4517 (1985); *b*) H. Wu, H. Nakamura, J. Kobayashi, Y. Ohizumi, Y. Hirata, *Experientia*, **42**, 855 (1986); *c*) M. Ishibashi, M. Tsuda, Y. Ohizumi, T. Sasaki, J. Kobayashi, *ibid.*, **47**, 299 (1991); *d*) J. Kobayashi, M. Tsuda, K. Agemi, H. Shigemori, M. Ishibashi, T. Sasaki, Y. Mikami, *Tetrahedron.*, **47**, 6617 (1991); *e*) M. Tsuda, H. Shigemori, M. Ishibashi, J. Kobayashi, *Tetrahedron Lett.*, **33**, 2597 (1992); *f*) M. Tsuda, H. Shigemori, M. Ishibashi, J. Kobayashi, *J. Nat. Prod.*, **55**, 1325 (1992).
7) G. Cimino, S. De Rosa, S. De Stefano, R. Self, G. Sodano, *Tetrahedron Lett.*, **24**, 3029 (1983).
8) J. Kobayashi, M. Tsuda, Y. Ohizumi, *Experientia*, **47**, 301 (1991).
9) M. Litaudon, M. Guyot, *Tetrahedron Lett.*, **27**, 4455 (1986).
10) L. Arabshahi, F. J. Schmitz, *J. Org. Chem.*, **52**, 3584 (1987).
11) S. Nishiyama, S. Yamamura, *Bull. Chem. Soc. Jpn.*, **58**, 3453 (1985).
12) J. A. McMillan, I. C. Paul, Y. M. Goo, K. L. Rinehart, Jr., *Tetrahedron Lett.*, **22**, 39 (1981).
13) C. W. J. Cheng, A. J. Weiheimer, *Tetrahedron Lett.*, **1977**, 4005.
14) E. Fattorusso, L. Minale, G. Sodano, *J. Chem. Soc., Chem. Commun.*, **1970**, 752.
15) R. J. Andersen, D. J. Faulkner, *Tetrahedron Lett.*, **1973**, 1175.
16) S. Tanaka, T. Okabe, S. Chieda, K. Endo, T. Kanoh, A. Okura, E. Yoshida, *Jpn. J. Cancer Res.*, **85**, 253 (1994).

NII-Electronic Library Service